- Home
- GCMG vs RIGL Comparison
GCMG vs RIGL Comparison
Compare GCMG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- RIGL
- Stock Information
- Founded
- GCMG 1971
- RIGL 1996
- Country
- GCMG United States
- RIGL United States
- Employees
- GCMG N/A
- RIGL N/A
- Industry
- GCMG Finance/Investors Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GCMG Finance
- RIGL Health Care
- Exchange
- GCMG Nasdaq
- RIGL Nasdaq
- Market Cap
- GCMG 604.3M
- RIGL 366.5M
- IPO Year
- GCMG N/A
- RIGL 2000
- Fundamental
- Price
- GCMG $12.68
- RIGL $19.91
- Analyst Decision
- GCMG Hold
- RIGL Buy
- Analyst Count
- GCMG 5
- RIGL 5
- Target Price
- GCMG $14.10
- RIGL $36.80
- AVG Volume (30 Days)
- GCMG 466.2K
- RIGL 219.4K
- Earning Date
- GCMG 05-06-2025
- RIGL 03-04-2025
- Dividend Yield
- GCMG 3.48%
- RIGL N/A
- EPS Growth
- GCMG N/A
- RIGL N/A
- EPS
- GCMG 0.03
- RIGL 0.99
- Revenue
- GCMG $511,735,000.00
- RIGL $179,278,000.00
- Revenue This Year
- GCMG $12.30
- RIGL $14.19
- Revenue Next Year
- GCMG $8.67
- RIGL $13.10
- P/E Ratio
- GCMG $128.44
- RIGL $20.64
- Revenue Growth
- GCMG 15.28
- RIGL 54.71
- 52 Week Low
- GCMG $8.53
- RIGL $7.48
- 52 Week High
- GCMG $14.48
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GCMG 34.22
- RIGL 45.28
- Support Level
- GCMG $12.48
- RIGL $18.44
- Resistance Level
- GCMG $13.14
- RIGL $20.88
- Average True Range (ATR)
- GCMG 0.29
- RIGL 1.55
- MACD
- GCMG -0.17
- RIGL -0.24
- Stochastic Oscillator
- GCMG 11.02
- RIGL 29.05
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.